374 Index Name Paper ref. Name Paper ref. Urbánek, K Tue 124, Tue 475 Urbanova, I Tue 222 Urbañska, A Tue 022 Urigüen, L Thu 399 Urquhart, B Tue 054 Urrutia, P Wed 152 Ursino, MR Thu 316, Thu 364 Uruno, A Tue 153 Ushijima, K Thu 268 Ushiki, T Mon 182 Usta, MP Mon 480 Ustenova, G Thu 336 Utkan, T Wed 351, Mon 387, Tue 145 Uurto, I Thu 223 Uyaiabasi, GN Wed 295 Uyanik, O Tue 461 Uydes Dogan, SB Thu 266 Uydes-Dogan, BS Mon 199 Uydes-Dogan, S Thu 269 Vaag, A Mon 406 Vaanhole, C Wed 002 Vach, W Tue 395 Vacher, B Tue 183, Tue 171, Tue 172 Vadodaria, K W01.2.4 Vahabi, S Thu 365 Vàhàkangas, K Mon 063 Vähäkangas, K Mon 076 Vahakoski, R Tue 429 Vaidya, VA W01.2.4 Vaillant, E Mon 161 Vainer, B Tue 480 Vainio, J Mon 256 Vainio, M Thu 079 Vainio, P Mon 410 Vainio, P Tue 436 Vainio, PJ Mon 256 Vaja, V Mon 221 Vajner, L Tue 445 Valadares, F Thu 323 Valant, C Thu 080 Valat, J-P Tue 198 Valdés, MA Mon 011 Valdivieso, A Wed 111 Valdizán, EM Wed 401 Valdizin, V Thu 408 Valdman, E Mon 462 Vale, N Thu 366, Tue 146, Tue 032 Valença, SS Wed 342 Valentin-Hansen, L Thu 036 Valenza, M FC18.4.6 Valera-Mota, MM Tue 025 Valérie, D Tue 190 Valinotto, ML Mon 128 Valle Cabrera, R Thu 424, Thu 425, Thu 394, Thu 395 van Breemen, C Wed 228, Thu 264 van Buchem, MA Mon 400 van den Anker, JN FC10.1.6, FC10.4.2 van denBrink, AM W13.1, Wed 292, Wed 220 van der Akker, R Thu 258 van der Lee, M Thu 085 van der Lei, J FC04.4.6 van der Saag, P Wed 446 van der Westhuizen, E W14.2 van der Westhuizen, ET Wed 080 van Dongen, Marloes GJ Tue 148 van Eps, N FC11.3.2 van Es, W FC10.4.6 van Essen, H Mon 212, Thu 208, Thu 221 van Eyk, A Tue 147 van Gerven, JMA FC17.3.5, Mon 400, FC10.4.6 van Grootheest, K FC13.1.1 van Hove, CE Wed 246, Wed 245 van Langen, J Wed 246, Wed 245 van Lipzig, M Thu 085 van Loenen, P Thu 082 van Overmeire, B Wed 006 van Patot, MT Mon 053 van Ree, JM W25.2 van Tiel, C FC18.2.4 van Veen, HW FC02.1.4 van Veen, T Wed 432, Tue 096 van Veldhoven, JP FC11.2.5 van Vuuren, SF Tue 279 van Westen, GJP FC11.4.6 van Wijhe, M Thu 216 van Winsen, MR FC11.2.5 van Zyl, J Wed 399 van Zyl, RL FC14.5.5. Mon 012, Tue 002, Tue 003, Tue 456, Tue 279 Vandeghinste, N Tue 280 Vandenberg, R Mon 052 Vandendriessche, K Wed 001 Vang, K Thu 405 Vanhaesebrouck, P Mon 365, Tue 306 Vanhanen, J FC14.3.6 Vanhaver, M Wed 002 Vanhoutte, F Tue 280 Vanhoutte, PMV IUL, FC15.2.6, YI.06, Thu 294, Thu 282, Thu 255, Tue 157, Thu 281, Wed 218, Thu 270, Mon 324 Vanina, M Wed 045 Vannacci, A Thu 302, Tue 093 Vannasaeng, S Tue 341 Vapaatalo, H Wed 361, FC16.3.4, Mon 302 Varanou, K Tue 230 Varela, M Wed 212, Tue 226 Varendi, H FC10.3.6 Varinska, L Thu 216, Tue 423 Varro, A W19.4, Wed 197, Wed 284, Mon 100 Varsamidis, K Mon 300 Varsamidou, E Mon 300 Vas, A Mon 027 Vas, Adam W24.2 Vasconcelos, V W31.4 Vashchinkina, EV Thu 194 Vasileiadis, M Tue 141 Vasilenko, GF Thu 253 Vasovic, V Mon 115, Tue 148, Wed 321 Vassileiadis, M Mon 187 Vathesatogkit, P Tue 127 Vauquelin, G Thu 426 Vaux, K FC08.1.6 Vavers, E Thu 189 Vavrinec, P Thu 097
Name Paper ref. Name Paper ref. Vaxillaire, M Mon 161 Vayssettes-Courchay, C Thu 273, Thu 274 Vaziri, B Mon 455 Vázquez, J Thu 271 Vazquez-Carrera, M Wed 440 Veale, E FC03.3.6 Vecera, R Wed 118 Veg, A Mon 371 Vegezzi, G Tue 258 Veiksina, S Tue 192 Veis, AA Mon 297 Veitia, AM Mon 038 Vekovischeva, OY Thu 194 Velasco, IT Wed 202, Wed 204, Wed 203, Mon 257 Velasco-Bejarano, B Mon 168 Velázquez, L Mon 023, W04.1.3 Velickovic-Radovanovic, R Tue 149 Vellecco, V Thu 081 Velo, G W32.5 Venner, M Tue 049 Ventura, S Mon 238, Tue 215 Vera, D Wed 152 Verbeuren, TJ Thu 273, Thu 274 Vercesi, J FC15.4.5, Wed 198 Verde, I Wed 211 Vereschagin, E Tue 167 Verleysdonk, S YI.02 Verli, J Wed 050 Vermetten, E FC17.5.3 Vermeulen, N W10.2 Verri Jr, W FC03.1.5 Verstraete, . A Tue 306 Verstraete, A Mon 365 Verstuyft, C W02.2.6, FC13.5.5, Tue 189 Vertkin, A Tue 267 Verzijl, D Thu 082 Vestri, A FC04.3.6 Vets, E Tue 280 Vey, JL FC11.3.2 Vial, T FC09.2.7, FC04.2.5 Viana, CTR Wed 302, Tue 428 Viana, G Mon 299 Viana, GSB Tue 281, Tue 282 Vidal, R Wed 401 Vidal, X FC14.4.5, Tue 087 Vie, B Tue 172 Viegas, M Mon 128 Vieira, C Thu 064 Vieira, R Mon 095, Mon 097, Mon 094 Vieira-Coelho, MA Wed 114, Thu 398 Vienberg, S FC05.3.5 Vieyra, A Tue 162 Viglinskaya, A Tue 150 Vilà, L Tue 133 Vilakkthala, R FC04.3.7 Vilar, B FC11.3.6, Thu 083 Vilas-Boas, OMGC Tue 101, Mon 010 Vilches-Flores, A Tue 149 Viljoen, M Thu 012, Thu 016 Villafaña-Godínez, L Mon 011 Villalba, N Thu 249, Tue 213 Villalobos-Molina, R Mon 168, Wed 049, Tue 025, Tue 150, Tue 149 Villalón, CM PL06, W13.3, Thu 022, Thu 203 Villamil-Hernández, MT Thu 203 Villamor, E Wed 226, Thu 217 Villarroya, M Mon 079 Villas-Boas, M Thu 366 Villier, C FC09.2.7 Vilskersts, R Mon 429 Vincent, F W03.3 Vinklerová, I Tue 475 Vinson, B Wed 382 Vinué, A W09.4 Viollet, B Thu 210 Virag, L Mon 100 Virtanen, S Tue 429 Vischer, H Thu 085 Visegrády, A Tue 078 Vistisen, J Thu 427 Vital, MABF Wed 394 Vitezic, D Tue 095, Tue 437 Vitezic, M Tue 095 Vitiello, M Thu 433 Vivoli, E Mon 113 Vizi, S Mon 460 Vlachos, G Tue 381 Vlahakis, JZ Tue 414, Vlahovic-Palèevski, V FC01.2.3 Vobruba, V Wed 017 Vogel, U Tue 480, Tue 482 Vohora, D Wed 419 Vohra, K FC09.5.5 Vokác, K Wed 386 Volkova, AV Wed 187 Vollmar, A Tue 227 Vollmar, AM FC16.1.5 Volpe, A Tue 487 von Ameln-Mayerhofer, A YI.02, Mon 463 von Moers, A Thu 013 Vora, A Tue 353, Mon 351 Voronin, M Thu 415 Voronina, TA Mon 422, Mon 462, Wed 187 Vorspan, F Wed 191 Vorum, H Wed 240 Vosmik, M Tue 421 Vosper, H Tue 232 Voss, TC FC18.4.2 Voss, U Thu 317 Voutilainen, MH Mon 341 Vovk, T FC07.3.5 Vrech, C Mon 280 Vreeburg, SA Wed 432 Vrioni, G Tue 457 Vucinic, S Tue 321 Vuckovic, S Mon 114 Vukmirovic Papuga, M Mon 115 Vukmirovic, S Mon 115, Tue 148, Tue 454 Vukovic, J Tue 091, Tue 151 Vukovic, MH Wed 435 Vuolteenaho, K FC09.2.5, Tue 283 Vuorela, P Mon 302 Vuorenpää, Ae Thu 084 Vural, K Wed 357 Vyas, R Mon 064 Vybiralova, Z Thu 168 Index 375
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317:
314 Index Name Paper ref. Name Pape
- Page 318 and 319:
316 Index Name Paper ref. Name Pape
- Page 320 and 321:
318 Index Name Paper ref. Name Pape
- Page 322 and 323:
320 Index Name Paper ref. Name Pape
- Page 324 and 325:
322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor